The award supports his work to develop cell-derived bioparticles into safe and efficient vehicles for delivering therapeutic proteins into cells. The award program supports promising, newly graduated scientists with the intellect, creativity, and maturity to bypass a traditional postdoctoral training period and instead launch an independent research career. Toward his ultimate goal of using bioparticles loaded with therapeutic proteins or RNAs to treat specific diseases, Raguram’s project seeks to understand factors that regulate bioparticle formation and to develop strategies for highly efficient bioparticle production. His previous work toward that goal earned Raguram recognition from the MIT Technology Review as one of its 2024 Innovators Under 35 — which recognized him for developing groundbreaking tools to make CRISPR genetic engineering more practical for treating a wide range of genetic disorders.